SIRT5 and breast carcinoma: Moreover, both human breast cancer cells (MDA-MB-231)and mouse myoblasts (C2C12) treated with compound 6 (50μM) displayed an increase in succinylated proteins as a resultof the inhibition of SIRT5 desuccinylase activity.84 In addition, treating MDA-MB-231 and C2C12 cells with compound 6 (50 μM) led to an increase in cellular glutamate andammonia levels via an increase GLS succinylation.